Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. He highlights improvements in our understanding of the biology of the disease, and how the resulting genetic knowledge impacts our stratification of aggresive MM.
